Table 4.

Cross-reactivity analysis of ADA

Patient ID	Age	Anti-ADL (µg/ml)	Control ID	Age	Anti-ADL (µg/ml)
438	29	<1.25	P*	48	<1.25
452	30	<1.25	F10	20	<1.25
485	64	<1.25	F22	25	<1.25
522	42	≤1.25	F28	22	<1.25
587	41	<1.25	F31	45	<1.25
609	30	<1.25	F32	59	<1.25
623	57	<1.25	F33	25	<1.25
626	57	<1.25	F38	53	<1.25
638	32	<1.25	F41	19	<1.25
639	33	<1.25	F42	32	<1.25
648	4	<1.25	F43	31	<1.25
652	31	<1.25	F44	44	<1.25
660	26	<1.25	F45	36	<1.25
681	?	<1.25	F46	35	<1.25
694	13	<1.25	F47	33	<1.25
695	37	<1.25
719	16	<1.25
721	?	<1.25
722	42	<1.25
724	80	<1.25

IFX-treated patient sera positive for anti-IFX antibodies and untreated healthy control sera were analyzed in an ELISA system for anti-adalimumab (ADL) antibody detection